News & Updates
Filter by Specialty:
![[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC](https://sitmspst.blob.core.windows.net/images/articles/amivantamab-plus-chemo-tied-to-better-outcomes-vs-chemo-alone-in-advanced-nsclc-e2167ed1-51a8-44c8-93d2-9f1c03576b98-square.jpg)
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
17 Sep 2024
Lung cancer screening tied to reduced mortality
In an observational study conducted in Poland, individuals who participated in a low-dose computed tomography (LDCT) lung cancer screening programme had a reduction in all-cause mortality compared with a matched control group extracted from a general Polish cohort.
Lung cancer screening tied to reduced mortality
16 Sep 2024
Arginine depletion plus chemo ups survival in rare lung cancer
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.
Arginine depletion plus chemo ups survival in rare lung cancer
13 Sep 2024
COVID-19 infection ups CV risk in people living with HIV
People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.